FY2024 Earnings Estimate for AURA Issued By Leerink Partnrs

Aura Biosciences, Inc. (NASDAQ:AURA) – Analysts at Leerink Partnrs raised their FY2024 earnings per share estimates for shares of Aura Biosciences in a report issued on Tuesday, November 12th. Leerink Partnrs analyst A. Berens now expects that the company will post earnings of ($1.67) per share for the year, up from their prior forecast of ($1.68). The consensus estimate for Aura Biosciences’ current full-year earnings is ($1.70) per share. Leerink Partnrs also issued estimates for Aura Biosciences’ Q4 2024 earnings at ($0.44) EPS, FY2025 earnings at ($1.93) EPS and FY2026 earnings at ($2.21) EPS.

Aura Biosciences (NASDAQ:AURA) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.02.

Other equities analysts also recently issued research reports about the company. HC Wainwright reiterated a “buy” rating and set a $22.00 price target on shares of Aura Biosciences in a research report on Thursday. JMP Securities increased their price target on Aura Biosciences from $19.00 to $23.00 and gave the stock a “market outperform” rating in a report on Friday, September 13th. BTIG Research boosted their price target on shares of Aura Biosciences from $21.00 to $24.00 and gave the stock a “buy” rating in a research note on Friday, October 18th. Evercore ISI upgraded shares of Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 16th. Finally, Scotiabank raised their price objective on Aura Biosciences from $20.00 to $23.00 and gave the stock a “sector outperform” rating in a report on Friday, October 18th. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $23.00.

Aura Biosciences Trading Down 5.0 %

Shares of Aura Biosciences stock opened at $9.47 on Friday. Aura Biosciences has a 12-month low of $6.63 and a 12-month high of $12.38. The firm has a market capitalization of $473.04 million, a price-to-earnings ratio of -5.47 and a beta of 0.33. The firm’s 50 day simple moving average is $9.82 and its two-hundred day simple moving average is $8.53.

Hedge Funds Weigh In On Aura Biosciences

Institutional investors have recently modified their holdings of the business. Long Focus Capital Management LLC raised its holdings in shares of Aura Biosciences by 113.4% in the 2nd quarter. Long Focus Capital Management LLC now owns 1,057,188 shares of the company’s stock valued at $7,992,000 after purchasing an additional 561,766 shares during the period. Levin Capital Strategies L.P. grew its holdings in shares of Aura Biosciences by 194.5% during the second quarter. Levin Capital Strategies L.P. now owns 327,466 shares of the company’s stock worth $2,476,000 after purchasing an additional 216,266 shares during the last quarter. Wellington Management Group LLP acquired a new stake in shares of Aura Biosciences in the third quarter valued at about $1,037,000. Bank of New York Mellon Corp raised its stake in Aura Biosciences by 51.4% during the second quarter. Bank of New York Mellon Corp now owns 143,027 shares of the company’s stock worth $1,081,000 after buying an additional 48,549 shares during the last quarter. Finally, Barclays PLC lifted its position in shares of Aura Biosciences by 256.5% during the 3rd quarter. Barclays PLC now owns 61,010 shares of the company’s stock valued at $544,000 after acquiring an additional 43,897 shares during the period. Institutional investors own 96.75% of the company’s stock.

Insider Activity

In related news, CTO Mark Plavsic sold 7,383 shares of the company’s stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $9.85, for a total transaction of $72,722.55. Following the completion of the sale, the chief technology officer now directly owns 121,132 shares of the company’s stock, valued at approximately $1,193,150.20. This represents a 5.74 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Los Pinos Elisabet De sold 9,200 shares of the business’s stock in a transaction dated Tuesday, October 29th. The shares were sold at an average price of $10.74, for a total value of $98,808.00. Following the transaction, the insider now owns 320,647 shares in the company, valued at $3,443,748.78. This represents a 2.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 67,259 shares of company stock valued at $780,699. Company insiders own 5.40% of the company’s stock.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.